Sign In
Buy VNRX
$2.08
-0.240 (-10.34%)
At Close: Jun 03, 2026
VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update
08:30am, Friday, 08'th Aug 2025
Conference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering
04:01pm, Monday, 04'th Aug 2025
HENDERSON, Nev. , Aug. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into de
Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation
08:00am, Wednesday, 16'th Jul 2025
HENDERSON, Nev., July 16, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides an update on the significant commercial and s
Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes
08:00am, Tuesday, 08'th Jul 2025
HENDERSON, Nev. , July 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it has demonstrated quantification of nucle
Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev. , June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epige
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
09:00pm, Wednesday, 04'th Jun 2025
HENDERSON, Nevada , June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q�
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
08:30am, Monday, 19'th May 2025
Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev. , May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today an
VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript
07:19pm, Friday, 16'th May 2025
VolitionRX Limited (NYSE:VNRX ) Q1 2025 Earnings Conference Call May 16, 2025 8:30 AM ET Company Participants Louise Batchelor – Chief Marketing and Communications Officer Terig Hughes – Chief Fin
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
05:37pm, Thursday, 15'th May 2025
Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
08:30am, Monday, 12'th May 2025
Conference call to take place on Friday, May 16 at 8:30 a.m. U.S Eastern Time Henderson, Nev.
HENDERSON, Nev. , May 7, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that Chief Commercial Officer, Gael Forterre,
HENDERSON, Nev. , April 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that President and Group Chief Executive O
VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript
12:31am, Tuesday, 01'st Apr 2025
VolitionRx Limited (NYSE:VNRX ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Louise Batchelor - Chief Marketing & Communications Officer Cameron Reynolds - President
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
04:05pm, Monday, 31'st Mar 2025
Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada , March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
08:00am, Friday, 28'th Mar 2025
Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and ho
